SLSN:NASDAQSolesence, Inc. Analysis
Data as of 2026-06-13 - not real-time
$1.33
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Solesence, Inc. (SLSN) is trading at a **price‑to‑earnings ratio of 133** despite a **trailing profit margin of only 1.6%** and a **negative revenue growth of 11% YoY** in Q1 2026. The company’s **gross margin has modestly improved to 26%**, yet the overall earnings picture remains weak, highlighted by a **net loss of $0.8 million** and **negative free cash flow**. Technical signals are mixed: the stock sits just above its 20‑day and 50‑day SMAs (1.2655 and 1.2636) but remains far below the 200‑day SMA (1.98), the **MACD histogram is bearish**, and **volume is on a decreasing trend**, suggesting limited buying pressure.
The high **beta of 2.47** and **30‑day volatility exceeding 110%** amplify price swings, while the **consumer defensive sector** offers some defensive cushion but does not offset the company‑specific operational challenges. With **no dividend** and a **debt‑to‑equity ratio over 130**, the balance sheet is strained, and the **max drawdown of 84%** underscores historic downside risk. Investors should weigh the short‑term price weakness against the potential upside from the company’s “Transform & Transcend” restructuring, which aims to lock in a **30% floor for gross margins**.
The high **beta of 2.47** and **30‑day volatility exceeding 110%** amplify price swings, while the **consumer defensive sector** offers some defensive cushion but does not offset the company‑specific operational challenges. With **no dividend** and a **debt‑to‑equity ratio over 130**, the balance sheet is strained, and the **max drawdown of 84%** underscores historic downside risk. Investors should weigh the short‑term price weakness against the potential upside from the company’s “Transform & Transcend” restructuring, which aims to lock in a **30% floor for gross margins**.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish MACD and decreasing volume
- High valuation multiples relative to earnings
- Continued revenue decline and net loss
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential margin floor from restructuring
- Improving gross margin despite lower sales
- Elevated volatility and beta limiting upside
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Strategic shift to higher‑margin products
- Absence of dividend and high debt load
- Sector defensive characteristics may provide stability
Key Metrics & Analysis
Financial Health
Revenue Growth-11.40%
Profit Margin1.56%
P/E Ratio133.0
ROE5.88%
ROA0.97%
Debt/Equity131.33
P/B Ratio5.3
Op. Cash Flow$171.0K
Free Cash Flow$-3867000
Technical Analysis
TrendNeutral
RSI53.2
Support$1.10
Resistance$1.41
MA 20$1.27
MA 50$1.26
MA 200$1.98
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86
Valuation
GradeOvervalued
TypeValue
Risk Assessment
Beta2.47
Volatility116.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.